IDO1-IN-19 (Compound 17) is an orally active IDO1 inhibitor with an IC50 of CYP2C9 of 8.64 µM. IDO1-IN-19 also acts funciton on cardiac channels, with IC50s of 12 µM (IKr), 40 µM (INa), 8.3 µM (ICa), respectively. IDO1-IN-19 has the potential to study cancer diseases[1].